Identification of barriers to insulin therapy and approaches to overcoming them

Russell‐Jones, David, Pouwer, Frans, Khunti, Kamlesh·2018·Diabetes, Obesity and Metabolism
DOI 10.1111/dom.13132

Cited by (238)

Items 101–200 of 238

  1. Oral insulin: time to rewrite the textbooks
    Chantal Mathieu · 2019 · The Lancet Diabetes & Endocrinology
  2. Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
    Pierre Gourdy, Amar Bahloul, Zahra Boultif, D. Gouet, Bruno Guerci · 2019 · Diabetes Therapy
  3. Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
    Richard J. MacIsaac · 2020 · Diabetes Therapy
  4. Factors associated with psychological insulin resistance among patients with type 2 diabetes in China
    Shilong Zhang, Xindan Zhang, Haipeng Wang, Wenyu Fan, Xingli Ma, Suhang Song, Beibei Zhang · 2024 · Frontiers in Endocrinology
  5. Managing Type 2 Diabetes Mellitus via the Regulation of Gut Microbiota: A Chinese Medicine Perspective
    Chester Yan Jie Ng, Linda L. D. Zhong, Han Seong Ng, Kia Seng Goh, Yan Xu Zhao · 2024 · Nutrients
  6. Diabetes, Therapeutic Inertia, and Patients’ Medication Experience
    Andrew S. Bzowyckyj, John E. Begert · 2020 · Diabetes Spectrum
  7. BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion
    Sarita Bajaj, Ashok Kumar Das, Sanjay Kalra, Rakesh Kumar Sahay, Banshi Saboo, Sambit Das, M. Shunmugavelu, Jubbin Jagan Jacob, Gagan Priya, Deepak Khandelwal et al. · 2019 · Diabetes Therapy
  8. A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan
    Fumika Shigiyama, Lei Liu, Helene Nordahl, Ryo Suzuki, Yuiko Yamamoto, Takahisa Hirose · 2021 · Diabetes Therapy
  9. A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy
    Susan Guzman · 2020 · Diabetes Spectrum
  10. Statistics: Can We Prove an Association for a Rare Complication?
    Margaret B. Hopwood · 1993 · Regional Anesthesia The Journal of Neural Blockade in Obstetrics Surgery & Pain Control
  11. Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
    Fang Liz Zhou, Charlie J. Nicholls, Lin Xie, Yuexi Wang, Neel Vaidya, Luigi Meneghini · 2019 · Endocrinology Diabetes & Metabolism
  12. Factors influencing insulin initiation in primary care facilities in Cape Town, South Africa
    Tasunungurwa T. Mathose, Robert James Mash · 2023 · South African Family Practice
  13. Feasibility and acceptability of the use of flash glucose monitoring encountered by Indigenous Australians with type 2 diabetes mellitus: initial experiences from a pilot study
    Audrey Eer, Rebecca Chia Yee Ho, Tracey Hearn, Mariam Hachem, Megan Freund, Luke James Burchill, Sharon Atkinson‐Briggs, Satpal Singh, Sandra Eades, Richard Charles O’Brien et al. · 2023 · BMC Health Services Research
  14. Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review
    Julio Rosenstock, HARPREET SINGH BAJAJ, Ildiko Lingvay, Simon R. Heller · 2024 · BMJ Open Diabetes Research & Care
  15. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial
    Liana K. Billings, Bue F. Ross Agner, Yüksel Altuntaş, Randi Grøn, Natalie Halladin, David Charles Klonoff, Nikolaοs Tentolouris, Esteban Jódar · 2020 · Journal of Diabetes Science and Technology
  16. Barriers to initiation of insulin therapy in poorly controlled type 2 diabetes based on self-determination theory
    Armin Rajab, Pegah Khaloo, Soghra Rabizadeh, Hamid Alemi, Salome Sadat Salehi‍, Reza Majdzadeh, Hossein Mirmiranpour, Assadollah Rajab, Alireza Esteghamati, Manouchehr Nakhjavani · 2020 · Eastern Mediterranean Health Journal
  17. What are the factors associated with long‐term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second‐line therapy? Results from the DISCOVER study
    Fabrice Bonnet, Hungta Chen, Andrew Cooper, Marília Brito Gomes, Linong Ji, Paul Leigh, Larisa Ramirez, Marina Vladimirovna Shestakova, Iichiro Shimomura, Afrah Siddiqui et al. · 2021 · Diabetes Obesity and Metabolism
  18. Assessing Barriers to Insulin Therapy among Omani Diabetic Patients Attending Three Main Diabetes Clinics in Muscat, Oman
    Abdullah Al Futaisi, Magdi E. Al-Osali, Ali Al-Kazrooni, Salim S. Al-Qassabi, Sumaia Al Gharabi, Sathiya Murthi Panchatcharam, Abdulaziz Mahmood Al-Mahrezi · 2021 · Sultan Qaboos University medical journal
  19. Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
    Hernando Vargas‐Uricoechea · 2022 · Journal of Clinical Medicine Research
  20. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
    Hui Shao, Abdul Jabbar Omar Alsaleh, TERRY A. DEX, Elisheva Lew, Vivian Andrew Fonseca · 2022 · Diabetes Therapy
  21. Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
    Gian Paolo Fadini, Olga Disoteo, Riccardo Candido, Paolo Di Bartolo, Luigi Laviola, Agostino Consoli · 2021 · Diabetes Therapy
  22. Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis
    Sandro Augusto Goncalves Ribeiro, Matheus Pedrotti, Larissa Calixto Hespanhol, Caroline Cristine Almeida Balieiro, Eric Paqualotto, Rodrigo Ribeiro e Silva, Mateus de Miranda Gauza, João Roberto de Sá · 2024 · Metabolism Open
  23. Burden of Current Insulin Therapy and Expectations for Future Insulin Therapy: Results from INBEING, a Web-Based Survey in Japan
    Yasuaki Hayashino, Satoshi Tsuboi, Yuiko Yamamoto, Hitoshi Ishii · 2024 · Diabetes Therapy
  24. Modeling the fasting blood glucose response to basal insulin adjustment in type 2 diabetes: An explainable machine learning approach on real-world data
    Camilla Heisel Nyholm Thomsen, Thomas Kronborg, Stine Hangaard, Peter Vestergaard, Ole Kristian Hejlesen, Morten Hasselstrøm Jensen · 2024 · International Journal of Medical Informatics
  25. Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin
    Sharmin Shabnam, Clare L. Gillies, Melanie Jane Davies, TERRY A. DEX, Eka Melson, Kamlesh K. Khunti, David R. Webb, Francesco Zaccardi, Samuel Seidu · 2023 · Diabetes Research and Clinical Practice
  26. ‘Is insulin right for me?’: Feasibility of a pilot randomised controlled trial and acceptability of a web‐based intervention to reduce psychological barriers to insulin therapy among adults with type 2 diabetes
    Elizabeth Holmes‐Truscott, Edith Eva Holloway, Hanafi Mohamad Husin, John Furler, Virginia L Hagger, Timothy Charles Skinner, Jane Speight · 2021 · Diabetic Medicine
  27. Implementing a Population Health Management Intervention to Control Cardiovascular Disease Risk Factors
    Shelley A. Jazowski, Hayden Barry Bosworth, Karen M. Goldstein, Courtney White‐Clark, Felicia McCant, Jennifer M. Gierisch, Leah L. Zullig · 2020 · Journal of General Internal Medicine
  28. Key Strategies for Overcoming Psychological Insulin Resistance in Adults with Type 2 Diabetes: The UK Subgroup in the EMOTION Study
    Elemer G. Balogh, Magaly Perez‐Nieves, Dachuang Cao, Irene Hadjiyianni, Nadeem Ashraf, Urvi S. Desai, Frank Jan Snoek, Jackie A. Sturt · 2020 · Diabetes Therapy
  29. The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
    Phil C. McEwan, Marc Evans · 2025 · Diabetes Obesity and Metabolism
  30. Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre ® System Initiation in Some People With Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy Without Insulin in France
    Jean‐Pierre Riveline, Fleur Levrat‐Guillen, B. Detournay, Éric Vicaut, Gérard de Pouvourville, Corinne Emery, Bruno Guerci · 2024 · Diabetes Technology & Therapeutics
  31. Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China
    Nan Dai, Xiaorong Su, Yong Wang · 2024 · Diabetes Obesity and Metabolism
  32. Real world evidence of insulin and biosimilar insulin therapy—Opportunities to improve adherence, outcomes and cost‐effectiveness
    Aimin Yang, Jiazhou Yu, Johnny T. K. Cheung, Juliana C.N. Chan, Elaine Chow · 2025 · Diabetes Obesity and Metabolism
  33. Long-Term Safety and Clinical Outcomes with Insulin Degludec/Insulin Aspart Treatment in Japanese Patients with Diabetes: A Real-World, Prospective, Observational Study
    Takuyuki Katabami, Kirsten Thorup Eriksen, Yuiko Yamamoto, Yasushi Ishigaki · 2021 · Advances in Therapy
  34. Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
    Samuel E. Dagogo-Jack, Robert C. Frederich, Jie Liu, Christopher Paul Cannon, Harry H. Shi, David Z.I. Cherney, Francesco Cosentino, URSZULA S. MASIUKIEWICZ, Ira Gantz, Richard E. Pratley · 2023 · The Journal of Clinical Endocrinology & Metabolism
  35. Determinants of excessive weight gain after the initiation of insulin therapy in type 2 diabetes mellitus: Retrospective inception cohort study (ZODIAC 60)
    Mireille A. Edens, Peter Ruben van Dijk, Eelko Hak, Henk J. G. Bilo · 2023 · Diabetes Research and Clinical Practice
  36. Therapy of Type 2 Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2024 · Experimental and Clinical Endocrinology & Diabetes
  37. Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial
    Jae Hyun Bae, Chang Ho Ahn, Ye Yang, Sun Joon Moon, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho · 2021 · Diabetes & Metabolism Journal
  38. Using a nurse-driven and home-based telehealth intervention to improve insulin therapy for people with type 2 diabetes in primary care: a feasibility study
    Patrick Ngassa Piotie, Paola Silvia Wood, Jane W. Muchiri, Elizabeth M. Webb, Paul Rheeder · 2022 · Journal of Endocrinology Metabolism and Diabetes of South Africa
  39. A Smartphone-Based Application to Assist Insulin Titration in Patients Undergoing Basal Insulin-Supported Oral Antidiabetic Treatment
    Dietrich Tews, Evanthia Gouveri, Jörg Simon, Cornelia Marck · 2022 · Journal of Diabetes Science and Technology
  40. Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials
    Hernando Vargas‐Uricoechea, Juan P. Frías, Hernando David Vargas-Sierra · 2023 · The Review of Diabetic Studies
  41. Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel
    Ádám Gyula Tabák, Péter Kempler, Cristian Guja, Roy Eldor, Martin Haluzı́k, Tomasz Klupa, Νικόλαος Παπάνας, Anca Pantea Stoian, Boris Mankovsky · 2024 · Diabetes Therapy
  42. Trial design and baseline data for LIRA‐PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting
    Jeff Unger, Dale C. Allison, Melissa Carlton, Kavitha Lakkole, Derek Lowe, Gerri Murphy, Jayant Kumar Panda, Mehmet Sargın, Margit S. Kaltoft, Marianne Bach Treppendahl et al. · 2019 · Diabetes Obesity and Metabolism
  43. Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial
    Anish Menon, Len Gray, Farhad Fatehi, Dominique Bird, Darsy Darssan, Mohan Karunanithi, Anthony William Russell · 2019 · Therapeutic Advances in Endocrinology and Metabolism
  44. Physician related barriers towards insulin therapy at primary care centres in Trinidad: a cross-sectional study
    Shastri Motilal · 2020 · BMC Family Practice
  45. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Monika Kellerer, Jens Aberle, Eva-Maria Fach, Baptist Gallwitz, Andreas Hamann, Hans‐Georg Joost, Harald Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck et al. · 2019 · Der Diabetologe
  46. Use of Concurrent Anti-diabetes Medications in Patients With Type 2 Diabetes in Clinical Practice in the United States
    Rakesh Luthra, Shaun D. Bender, Derek Terada · 2022 · Clinical Therapeutics
  47. The diabetes insulin self-management education (DIME) intervention for people with type 2 diabetes starting insulin: a pilot feasibility randomised controlled trial
    K. Winkley, Taru Sorsa, Qingxiu Tian, Ilse Reece, Christina Fitzgerald, M. Chamley, K. Ismail, A. Forbes, R. Upsher · 2023 · Pilot and Feasibility Studies
  48. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
    ALICE Y.Y. CHENG, Stewart B. Harris, Francesco Giorgino, Jochen Seufert, Robert A. Ritzel, Kamlesh K. Khunti, Felipe Lauand, Lydie Melas‐Melt, Jukka Westerbacka, Zsolt Bosnyák et al. · 2019 · Diabetes Obesity and Metabolism
  49. Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies
    Linong Ji, Yan Bi, Shandong Ye, Yun Huang, Xia Zhang, Shuhua Shang, Nan Cui, Huiqiu Yin, Minlu Zhang · 2021 · Diabetes Research and Clinical Practice
  50. ¿La insulina es un todoterreno?
    Ana María Cebrián Cuenca · 2021
  51. Association between hyperglycemia treatment and mortality in patients with diabetes and COVID-19 in a Peruvian hospital: A retrospective cohort study
    Eddy López-Huamanrayme, Dioni Garate, Frank Espinoza‐Morales, Sharon Del-Castillo-Ochoa, Andrés Alberto Gómez-Noronha, Elizabeth Salsavilca, Álvaro Taype-Rondán, Francisco J. Pasquel · 2021 · Journal of Clinical & Translational Endocrinology
  52. Cómo podemos optimizar la insulinización
    Pilar Buil Cosiales · 2021
  53. Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real‐world observational study
    Sharmin Shabnam, Sophia C. Abner, Clare L. Gillies, Melanie Jane Davies, TERRY A. DEX, Kamlesh K. Khunti, David R. Webb, Francesco Zaccardi, Samuel Seidu · 2023 · Diabetes Obesity and Metabolism
  54. Pharmacological characteristics of once‐weekly insulin icodec in Japanese individuals with type 1 diabetes
    Takashi Eto, Miwa Haranaka, Niels Rode Kristensen, Andrea Navarria, Tomoyuki Nishida, Rasmus Ribel‐Madsen, Stinne Byrholdt Søgaard, Inge B. Halberg · 2024 · Journal of Diabetes Investigation
  55. Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis
    Saaed Abunada, Sheela Bai, Usha Kumari, Fnu Nancy, Areeba Khan, Nikeeta Bai, F. N. U. Shevani, Anusha Bai, Shah Dev, Noshad Zain Ul Abiddin et al. · 2025 · Endocrinology Diabetes & Metabolism
  56. Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis
    D. Raccah, Bruno Guerci, Mayank Ajmera, Keith L. Davis, Juliana Meyers, Elisheva Lew, Alka Shaunik, Lawrence Blonde · 2019 · Endocrinology Diabetes & Metabolism
  57. Prevalence of depression among type2 diabetes mellitus in Pakistani population
    Abid Naeem, Muhammad Shuaib, Subtain-Ul-Hassan Abid, Muhammad Huzaifa Abid, Muhammad Imran · 2019 · The Professional Medical Journal
  58. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study)
    Masato Odawara, Munehide Matsuhisa, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi · 2020 · Expert Opinion on Pharmacotherapy
  59. Effectiveness and safety of insulin glargine Gla-300 in insulin-naïve type 2 diabetes subjects in a real-life setting—the GOAL_RO trial
    for the GOAL_RO Study Group, Daniela Stegaru, Simona Nicodim, Delia Vladu, Olimpia Guțu, Adriana Gabriela Onaca, Florina Pîrvu, Mihaela Moise, Cristian Guja · 2021 · Annals of Translational Medicine
  60. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2022 · Die Diabetologie
  61. Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 ( BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
    Rory J. McCrimmon, Philip Home, ALICE Y.Y. CHENG, Francesco Giorgino, Vivian Andrew Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard, Julio Rosenstock · 2022 · Diabetes Obesity and Metabolism
  62. Attitudes and beliefs of South African primary healthcare practitioners on initiating insulin in people with type 2 diabetes: Findings from the Tshwane Insulin Project (TIP)
    Patrick Ngassa Piotie, Paola Silvia Wood, Jane W. Muchiri, Elizabeth M. Webb, Paul Rheeder · 2021 · Primary care diabetes
  63. Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial
    IRENE M. HRAMIAK, Hertzel C. Gerstein, Lawrence A. Leiter, Jean‐François Yale, HARPREET SINGH BAJAJ, John A. Stewart, Marie-Josée Toutounji, Stewart B. Harris · 2022 · Diabetes Obesity and Metabolism
  64. Out-of-Pocket Spending for Insulin by Medicare Beneficiaries After Monthly Caps
    Dongzhe Hong, Krystal Cantos, Diana Morgenstern, Sonali Dasgupta, Aaron Seth Kesselheim, Zirui Song, Angela Y. Tong, Rohit Chadaram, Danielle M. Potter, Elisabetta Patorno et al. · 2026 · JAMA Internal Medicine
  65. Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus
    Sung-Chen Liu, Shih‐Ming Chuang, Chao‐Hung Wang, Ming-Nan Chien, Chun‐Chuan Lee, Wei‐Che Chen, Ching-Hsiang Leung, Jiun‐Lu Lin · 2022 · Diabetes Obesity and Metabolism
  66. What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art
    Christiano Argano, Laura Priola, Francesco Manno, Salvatore Corrao · 2024 · Biomedicines
  67. Open questions on basal insulin therapy in T2D: a Delphi consensus
    Delphi Board, Aglialoro Alberto, Anichini Roberto, Avogaro Angelo, Cristiana Baggiore, berra cesare, Riccardo C. Bonadonna, Corrao Salvatore Maria Giuseppe, Da Porto Andrea, De Candia Lorenzo et al. · 2024 · Acta Diabetologica
  68. Pharmacokinetic properties of once‐weekly insulin icodec in Chinese individuals with type 2 diabetes
    Yijun Li, Ariel Fu, Shan Jiang, Ann‐Katrine Kjærsgaard Jøns, Beibei Liang, Qi Ni, Rasmus Ribel‐Madsen, Lisbet Westergaard · 2025 · Journal of Diabetes Investigation
  69. Clinical Use of IDegLira: Initiation to Titration After Basal Insulin
    Mark Warren, Donna Steel · 2019 · Clinical Diabetes
  70. Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
    Stewart B. Harris, Erika Bezerra Parente, Janaka J. Karalliedde · 2022 · Diabetes Therapy
  71. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/ mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real‐world evidence study from Saudi Arabia ( EVOLUTION )
    Faisal Al Malki, Bandar El Damanhoury, Abdallah Othman, Zain Alghamdi, Majed AlQahtani, Amr Madgy, Mohamed Zahir Chouikrat · 2023 · Diabetes Obesity and Metabolism
  72. Efficacy and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: The INITIATION study
    Liming Chen, Binhong Wen, Haixia Liu, Hongmei Wu, Binhong Duan, Hongyan Shu, Qiu Zhang, Xiaohong Wu, Min Li, Yanfang Han et al. · 2024 · Diabetes Obesity and Metabolism
  73. Individualised targets for insulin initiation in type 2 diabetes mellitus—the influence of physician and practice: a cross-sectional study in eight European countries
    Anne Meike Boels, E. J. P. De Koning, Rimke C. Vos, Kamlesh K. Khunti, Guy E.H.M. Rutten · 2019 · BMJ Open
  74. Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy
    Gaetano Leto, Ilaria Barchetta, Lorenzo De Candia, Maria Grazia Magotti, Marco Cianciullo, Roberta Manti, Carlo Negri, Vincenzo Cimino, Alessandro Roberto Dodesini, Francesco Zerella et al. · 2021 · Diabetes Therapy
  75. Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
    Olesya Y. Gurova, Valentin V. Fadeev, Ekaterina S. Maloletkina · 2019 · Diabetes Mellitus
  76. Psychological insulin resistance and affecting factors in patients with type 2 diabetes
    Seher Çevik Aktura, Gürkan Özden · 2022 · Journal of Human Sciences
  77. Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program
    Eden M Miller, Michael B. Davidson, HARPREET SINGH BAJAJ, Julio Rosenstock, Athena Philis‐Tsimikas, Richard M. Bergenstal, Michael G. Case, Liza Ilag, Rebecca J. Threlkeld, Esther M. Levasseur et al. · 2026 · Diabetes Therapy
  78. Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS
    Andrea Giaccari, Riccardo C. Bonadonna, Raffaella Buzzetti, Gianluca Perseghin, Domenico Cucinotta, Carmine Giuseppe Fanelli, Angelo Avogaro, Gianluca Aimaretti, Monica Larosa, V. Pagano et al. · 2021 · Acta Diabetologica
  79. ‘Is Insulin Right for Me?’: Web‐based intervention to reduce psychological barriers to insulin therapy among adults with non‐insulin‐treated type 2 diabetes—A randomised controlled trial
    Elizabeth Holmes‐Truscott, Edith Eva Holloway, Benjamin Lam, Shaira Nicole Baptista, John Furler, Virginia L Hagger, Timothy Charles Skinner, Jane Speight · 2023 · Diabetic Medicine
  80. Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China
    Lixin Guo, Liming Chen, Fan Zhao, Xiaoyun Liu, Hongcheng Ding, Kun Wang, Xing Zhong, Vinay Babu Shankarappa, Gaurav Chaudhary · 2024 · Diabetes Obesity and Metabolism
  81. Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 Diabetes
    Risa Nasu, Tomonori Oura, Kenji Ohwaki, Makoto Imori, Kenichi Furihata · 2025 · Diabetes Therapy
  82. Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomized controlled trial
    Atthayaporn Choomai, Apichai Wattanapisit, Orathai Tiangtam · 2020 · Romanian Journal of Internal Medicine
  83. Descriptive study of a clinical and educational telemedicineintervention in patients with diabetes receiving glargine 300U/ml (Toujeo) in Spain: results of the T-Coach programme
    Virginia Bellido, Cristóbal Morales, Araceli Muñoz‐Garach, José Manuel García Almeida, Juan Luís Fernández-Morera, Beatriz González Aguilera, Martín López de la Torre, Diego Bellido · 2023 · Drugs in Context
  84. A New Once-Weekly Insulin — Its Effectiveness and Safety
    Irwin G. Brodsky · 2024 · New England Journal of Medicine
  85. Therapie des Typ-2-Diabetes
    R. Landgraf, M. Kellerer, E. Fach, B. Gallwitz, A. Hamann, H. Joost, H. Klein, D. Müller-Wieland, M. Nauck, H. Reuter et al. · 2013 · Diabetologie und Stoffwechsel
  86. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2023 · Die Diabetologie
  87. Patient’s barrier to initiate insulin therapy for type 2 D.M.
    Ruqaya Adnan Salih, Anmar B. Al-Dewachi, Zaid Muayad Yassen, Saad Abdul-Razzak Ibrahim · 2024 · Irish Journal of Medical Science (1971 -)
  88. Real-World Effectiveness of My Dose Coach™-Assisted Basal Insulin Titration in People with Type 2 Diabetes in Saudi Arabia and Kuwait
    Mohammed E. Al‐Sofiani, Mohammed S. Almehthel, Ebaa Al‐Ozairi, Jamaa Sadik, Lichen Hao, Yasser A. Akil · 2025 · Diabetes Therapy
  89. IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis
    Yang Liu, Xuejing Li, Jie Yang, Suhui Qie, Xiaoli Wang, Xianying Wang, Yingying Zheng · 2025 · Frontiers in Endocrinology
  90. Material-driven glucose responsiveness in insulin delivery systems: carrier selection and performance
    Zhi-Han Li, Jing-Ge Jiang, Zi-Yu Zhu, Cheng Luo, Chun Xu, Chuan-Pin Chen, Guo-Qin Ren, Ruo-Fei Huang, Dong-Juan He · 2026 · Frontiers in Endocrinology
  91. Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials
    Linong Ji, J. S. Andersen, Malik Benamar, Paola Ponzani, A. G. Unnikrishnan, SIRI M. VINTHER, Rosangela Roginski Rea · 2026 · Diabetes Obesity and Metabolism
  92. Diabetic care delivery with package of essential noncommunicable diseases interventions protocol in rural Nepal: A district hospital-based study
    Pawan Kumar Bajaj Agrawal, Priyanka Gupta, Bikash Gauchan, Biplav Shrestha · 2018 · International Journal of Noncommunicable Diseases
  93. Solutions thérapeutiques pour un patient diabétique de type 2 mal contrôlé sous une combinaison metformine plus gliptine
    André Jacques Scheen · 2019 · Médecine des Maladies Métaboliques
  94. Comparación de Inercia Terapéutica en Diabetes Mellitus Tipo 2 entre Médicos de Atención Primaria y Endocrinólogos. Una Revisión de la Literatura.
    Lizeth Anabel Sánchez Santana, Cristina Vanessa Aguirre Aragón, Edison Tarquino Ramos Tituaña · 2022 · Revista Científica y Tecnológica UPSE
  95. COMBINSI (COMBat to INSufficient Insulin therapy) – A Portuguese project in type 2 diabetes
    Francisco Simões de Carvalho, Francisca de Brito Marques, Joana Lima Ferreira, Ana Elisa Lopes, Rosa Maria Príncipe · 2023 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  96. "Unmet needs" in der Therapie des Diabetes mellitus Typ 2
    Jens Aberle · 2023 · MMW - Fortschritte der Medizin
  97. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2024 · Die Diabetologie
  98. Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
    Daisuke Yabe, Munehide Matsuhisa, Yoko Takahashi, Yukiko Morimoto, Yasuo Terauchi · 2024 · Diabetes Therapy
  99. Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung
    Jochen Seufert, Ingrid Dänschel, Stefan Gölz, Nicola Haller, Bernhard Kulzer, Susanne Tan, Oliver Schnell, Tobias Wiesner, Jens Kroeger · 2024 · Diabetologie und Stoffwechsel
  100. A real world STudy of ADherence to Insulin in diabetic hUMans-STADIUM study
    Dipsanker Chatterjee, Subham Das · 2024 · Digital Journal of Clinical Medicine